Melloney J. Dröge
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
Melloney J. Dröge has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Wilhelmus Johannes Quax
University of Groningen
2 shared publications Adriaan A. van Sorge
1 shared publication- Herman J. Woerdenbag
Department of Pharmaceutical Technology and Biopharmacy, Groningen Research Institute of Pharmacy (GRIP), University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands
1 shared publication Johan Zaagsma
1 shared publicationNicolaas J. van Haeringen
1 shared publication- Rein Bos
Department of Pharmaceutical Biology, Groningen Research Institute of Pharmacy, Groningen University Institute for Drug Exploration, A. Deusinglaan 1, 9713 AV Groningen, The Netherlands
1 shared publication
Latest Publications
- 23 June 2003
- Published by Wiley in Journal of Separation Science
- Vol. 26 (9-10) , 771-776
Chiral gas chromatography for the determination of 1,2‐O‐isopropylidene‐sn‐glycerol stereoisomers
- 23 June 2003
- Published by Wiley in Journal of Separation Science
- Vol. 26 (9-10) , 771-776
Chiral gas chromatography for the determination of 1,2‐O‐isopropylidene‐sn‐glycerol stereoisomers
- 25 April 2003
- Published by S. Karger AG in Ophthalmic Research
- Vol. 35 (3) , 160-163
Alternative Splicing of Cyclooxygenase-1 mRNA in the Human Iris
In homogenates of the human iris, the nonsteroidal anti-inflammatory drug (NSAID) S(+)flurbiprofen has been reported to inhibit cyclooxygenase-1 (COX-1) 70-fold more potently than in human whole blood. We hypothesized that this difference may be due to alternative splicing of COX-1 mRNA in the human iris or in whole blood. In this study, we have identified a similar COX-1 splice variant (COX-1SV) in both tissues with comparable COX-1/COX-1SV expression ratios. Therefore, we conclude that the difference in IC50 values of S(+)flurbiprofen towards COX-1 in the human iris and human whole blood is not related to differences in the occurrence of spliced COX-1.
- 25 April 2003
- Published by S. Karger AG in Ophthalmic Research
- Vol. 35 (3) , 160-163
Alternative Splicing of Cyclooxygenase-1 mRNA in the Human Iris
In homogenates of the human iris, the nonsteroidal anti-inflammatory drug (NSAID) S(+)flurbiprofen has been reported to inhibit cyclooxygenase-1 (COX-1) 70-fold more potently than in human whole blood. We hypothesized that this difference may be due to alternative splicing of COX-1 mRNA in the human iris or in whole blood. In this study, we have identified a similar COX-1 splice variant (COX-1SV) in both tissues with comparable COX-1/COX-1SV expression ratios. Therefore, we conclude that the difference in IC50 values of S(+)flurbiprofen towards COX-1 in the human iris and human whole blood is not related to differences in the occurrence of spliced COX-1.